Biopharmaceutical
Obesity
Development
Unitedstates
Treatments
M&A Advisory
Lazard
Full Credential Description
Orexigen. United States. Announced Date 23/07/2009. Closed Date 28/07/2009. Deal value: $75m. Underwritten registered direct/follow-on offering of common stock. Industry: Orexigen was a biopharmaceutical company focused on developing treatments for obesity.